Women are twice as likely as men to be diagnosed with MS and 450,000 women in Europe are affected by the condition. CRA investigated the burden of MS on women patients and the implications on Europe’s economy and society. Our research found a significant impact for women in terms of their family life, career progression and labour market role, that is not recognised by current MS polices. Our analysis suggests a need for greater awareness initiatives to drive early diagnosis and multidisciplinary treatment approaches to facilitate timely access to care. Also, social and workplace support can increase participation in the labour force and social activities, supporting women, their families and the wider economy.
Evidence requirements for orphan drugs
CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence...